Insurance Companies Shouldn’t Seek Genetic Test Results, Says Privacy Watchdog
By Steve Rennie,
The Canadian Press
| 07. 10. 2014
OTTAWA—Canada’s privacy watchdog is urging insurance companies and others to stop asking for access to the results of existing genetic tests at this time.
Privacy Commissioner Daniel Therrien says it is becoming more of a challenge to protect people’s genetic privacy with recent advances in science and technology.
“We are calling on the industry to refrain from asking for existing test results to assess insurance risk until the industry can clearly show that these tests are necessary and effective in assessing risk,” Therrien said in a statement Thursday.
“This would
allow people to undergo genetic testing for various purposes without fear that the results may have a negative impact if they apply for insurance.”
There are now hundreds of genetic tests available to help spot genes known to increase a person’s risk of developing certain medical conditions.
But some people may decline tests for fear a positive result may mean they could face discrimination from insurance companies or their employers.
“It is not reasonable and not necessary for the insurance industry to ask for genetic information when they’re making their...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...